Literature DB >> 10545427

Downregulation of the Na(+)-creatine cotransporter in failing human myocardium and in experimental heart failure.

S Neubauer1, H Remkes, M Spindler, M Horn, F Wiesmann, J Prestle, B Walzel, G Ertl, G Hasenfuss, T Wallimann.   

Abstract

BACKGROUND: The failing myocardium is characterized by depletion of phosphocreatine and of total creatine content. We hypothesized that this is due to loss of creatine transporter protein. METHODS AND
RESULTS: Creatine transporter protein was quantified in nonfailing and failing human myocardium (explanted hearts with dilated cardiomyopathy [DCM; n=8] and healthy donor hearts [n=8]) as well as in experimental heart failure (residual intact left ventricular tissue, rats 2 months after left anterior descending coronary artery ligation [MI; n=8] or sham operation [sham; n=6]) by Western blotting. Total creatine content was determined by high-performance liquid chromatography. Donor and DCM hearts had total creatine contents of 136.4+/-6.1 and 68.7+/-4.6 nmol/mg protein, respectively (*P<0.05); creatine transporter protein was 25.4+/-2.2 optical density units in donor and 17.7+/-2.5 in DCM (*P<0.05). Total creatine was 87.5+/-4.2 nmol/mg protein in sham and 65.7+/-4.2 in MI rats (*P<0.05); creatine transporter protein was 139.0+/-8.7 optical density units in sham and 82.1+/-4.0 in MI (*P<0.05).
CONCLUSIONS: Both in human and in experimental heart failure, creatine transporter protein content is reduced. This mechanism may contribute to the depletion of creatine compounds and thus to the reduced energy reserve in failing myocardium. This finding may have therapeutic implications, suggesting a search for treatment strategies targeted toward creatine transport.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10545427     DOI: 10.1161/01.cir.100.18.1847

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  34 in total

1.  Downregulation of the creatine transporter SLC6A8 by JAK2.

Authors:  Manzar Shojaiefard; Zohreh Hosseinzadeh; Shefalee K Bhavsar; Florian Lang
Journal:  J Membr Biol       Date:  2012-03-11       Impact factor: 1.843

Review 2.  Mitochondrial centrality in heart failure.

Authors:  José Marín-García; Michael J Goldenthal
Journal:  Heart Fail Rev       Date:  2008-01-05       Impact factor: 4.214

Review 3.  New aspects of impaired mitochondrial function in heart failure.

Authors:  Mariana G Rosca; Charles L Hoppel
Journal:  J Bioenerg Biomembr       Date:  2009-04       Impact factor: 2.945

4.  Experimentally observed phenomena on cardiac energetics in heart failure emerge from simulations of cardiac metabolism.

Authors:  Fan Wu; Jianyi Zhang; Daniel A Beard
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-08       Impact factor: 11.205

Review 5.  Energy metabolism in heart failure and remodelling.

Authors:  Joanne S Ingwall
Journal:  Cardiovasc Res       Date:  2008-11-05       Impact factor: 10.787

6.  Oral creatine supplementation facilitates the rehabilitation of disuse atrophy and alters the expression of muscle myogenic factors in humans.

Authors:  P Hespel; B Op't Eijnde; M Van Leemputte; B Ursø; P L Greenhaff; V Labarque; S Dymarkowski; P Van Hecke; E A Richter
Journal:  J Physiol       Date:  2001-10-15       Impact factor: 5.182

7.  Creatine--a dispensable metabolite?

Authors:  Heinrich Taegtmeyer; Joanne S Ingwall
Journal:  Circ Res       Date:  2013-03-15       Impact factor: 17.367

Review 8.  Energy metabolism in heart failure.

Authors:  Renée Ventura-Clapier; Anne Garnier; Vladimir Veksler
Journal:  J Physiol       Date:  2003-12-05       Impact factor: 5.182

9.  Creatine transporters: a reappraisal.

Authors:  Oliver Speer; Lukas J Neukomm; Robyn M Murphy; Elsa Zanolla; Uwe Schlattner; Hugues Henry; Rodney J Snow; Theo Wallimann
Journal:  Mol Cell Biochem       Date:  2004 Jan-Feb       Impact factor: 3.396

Review 10.  Heart Failure in Type 2 Diabetes Mellitus.

Authors:  Helena C Kenny; E Dale Abel
Journal:  Circ Res       Date:  2019-01-04       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.